113 results
Page 4 of 6
424B5
nj0xzzwld70l2oz
9 Feb 22
Prospectus supplement for primary offering
4:08pm
8-K
EX-99.1
syd9iyq
6 Dec 21
Aeglea BioTherapeutics Announces Achievement of Primary Endpoint in Phase 3 Study of Pegzilarginase in Patients with Arginase 1 Deficiency
6:30am
8-K
EX-99.2
xzwxp0sm2qk
6 Dec 21
Aeglea BioTherapeutics Announces Achievement of Primary Endpoint in Phase 3 Study of Pegzilarginase in Patients with Arginase 1 Deficiency
6:30am
8-K
pqjxr
6 Dec 21
Aeglea BioTherapeutics Announces Achievement of Primary Endpoint in Phase 3 Study of Pegzilarginase in Patients with Arginase 1 Deficiency
6:30am
8-K
EX-99.2
2s3gns2dexngy8
18 Mar 21
Aeglea BioTherapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Highlights
8:31am
8-K
EX-99.2
jaryznz0
26 May 20
Regulation FD Disclosure
8:30am
424B5
bfq5vluy 4a
28 Apr 20
Prospectus supplement for primary offering
4:10pm
424B5
rlh7wa 9ndx09
27 Apr 20
Prospectus supplement for primary offering
4:09pm
8-K
aipvvnvjd oh
16 Apr 20
Entry into a Material Definitive Agreement
8:49am